Group 1 - The company held its 22nd meeting of the fifth board of directors on December 24, 2025, where all five directors attended, and the meeting complied with relevant laws and regulations [2][4]. - The board approved the proposal not to adjust the conversion price of the convertible bonds, "Meinuo Convertible Bonds" [3][5]. - The decision was made despite the stock price being below the conversion price threshold, which triggered the adjustment clause [9][16]. Group 2 - As of December 24, 2025, the company's stock had closed below 90% of the current conversion price (25.68 CNY/share) for at least 15 out of the last 30 trading days, indicating a potential adjustment [9][16]. - The next period for triggering the conversion price adjustment clause will restart from December 25, 2025, and the board will decide on any future adjustments if triggered again [9][16]. - The initial conversion price of the "Meinuo Convertible Bonds" was set at 37.47 CNY/share, with subsequent adjustments made over time due to various corporate actions [10][11].
宁波美诺华药业股份有限公司第五届董事会第二十二次会议决议公告